Cargando…
GD2 Expression in Medulloblastoma and Neuroblastoma for Personalized Immunotherapy: A Matter of Subtype
SIMPLE SUMMARY: Molecular analyses discussed in Molecular Tumor Boards are expected to improve cancer treatment by identifying tumor-specific alterations. Here, we quantified the expression of the gangliosides GD2 and N-glycolyl GM3 in neuroblastoma and medulloblastoma, two aggressive pediatric tumo...
Autores principales: | Paret, Claudia, Ustjanzew, Arsenij, Ersali, Sara, Seidmann, Larissa, Jennemann, Richard, Ziegler, Nicole, Malki, Khalifa El, Russo, Alexandra, Wingerter, Arthur, Ortmüller, Franziska, Bornas, Angelina, Wehling, Pia Charlotte, Lepădatu, Adina, Ottenhausen, Malte, Roth, Wilfried, Sommer, Clemens, Fliss, Barbara, Frauenknecht, Katrin B. M., Sandhoff, Roger, Faber, Jörg |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775636/ https://www.ncbi.nlm.nih.gov/pubmed/36551537 http://dx.doi.org/10.3390/cancers14246051 |
Ejemplares similares
-
Glucosylceramide Synthase Inhibitors Induce Ceramide Accumulation and Sensitize H3K27 Mutant Diffuse Midline Glioma to Irradiation
por: El Malki, Khalifa, et al.
Publicado: (2023) -
Interaction between Bacteria and the Immune System for Cancer Immunotherapy: The α-GalCer Alliance
por: Ustjanzew, Arsenij, et al.
Publicado: (2022) -
Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1
por: Paret, Claudia, et al.
Publicado: (2021) -
HGG-03. THE GLYCOSPHINGOLIPIDS METABOLISM IS A NOVEL TARGET IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
por: Paret, Claudia, et al.
Publicado: (2021) -
Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL
por: Ziegler, Nicole, et al.
Publicado: (2023)